Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday

NCT01854086 | Unknown

• 1 other identifier: MMC130009-13CTIL
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to provide information about the rate of response and persistence to drug therapies for osteoporosis. Another issue examined in this study refers to the preferences and concerns about future treatments in patients during "drug holiday".

Conditions

Osteoporosis

Keywords

osteoporosis; postmenopausal; patient compliance; compliance; diphosphonates; bisphosphonates

Outcome Measures

Primary Outcomes (1)

• Compliance and persistence to osteoporosis drug therapy

  Data collection will be done by questionnaires and from the medical record of the patient. The information collected will include: demographic information, measurements of bone density, additional information about the disease and treatment that the patient receives,prescription purchases and additional drugs the patient is taking (steroids, PPI's(Proton Pump Inhibitors) / H2 receptor antagonists and NSAIDs(Non Steroidal Anti Inflammatories)).

  Participants will be followed for the duration of their clinic visit, an average of 5 hours

Study Arms (1)

Postmenopausal women

Postmenopausal women treated with bisphosphonates

Other: Questionnaires about compliance and persistence with bisphosphonates treatment

Interventions

Questionnaires about compliance and persistence with bisphosphonates treatment OTHER

Postmenopausal women

Eligibility Criteria

• Age: 40 Years - 90 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with osteoporosis,who been treated in Endocrinology Clinic of Medical Center

You may qualify if:

• Postmenopausal women
• Diagnosis of osteoporosis in the medical record
• At least one prescription drug to treat osteoporosis in the last 5 years
• Insured by "Clalit" Health Services
• Hebrew-speaking capability and readiness to answer a questionnaire

You may not qualify if:

• Premenopausal women
• No diagnosis of osteoporosis in the medical record
• No treatment for osteoporosis in the last 5 years
• Women who do not speak Hebrew or are unable to answer a questionnaire

Sponsors & Collaborators

• Meir Medical Center: lead

Study Sites (1)

Meir medical center the clalit health care services group

Kfar Saba, 44281, Israel

Location

Related Publications (1)

• Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005 Sep;21(9):1453-60. doi: 10.1185/030079905X61875.

  PMID: 16197664 RESULT

MeSH Terms

Conditions

Osteoporosis; Patient Compliance

Condition Hierarchy (Ancestors)

Bone Diseases, Metabolic; Bone Diseases; Musculoskeletal Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases; Patient Acceptance of Health Care; Treatment Adherence and Compliance; Health Behavior; Behavior

Central Study Contacts

Pnina Rotman, M.D

CONTACT

972-57-7482609; Pnina.Rotman@clalit.org.il

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 6, 2013
• First Posted: May 15, 2013
• Study Start: September 1, 2013
• Primary Completion: February 1, 2014
• Last Updated: May 15, 2013

Record last verified: 2013-05

Locations

IL (1)